IP Library Granted Patent US 12,038,434
Granted Patent B2
US 12,038,434 · App. 15/549,975 · Granted Jul 16, 2024

Devices, solutions and methods for sample collection related applications, analysis and diagnosis

Inventors: Stephen Andrews (Falmouth, ME); Youssef Biadillah (Geneva, CH); Manasi Jain (Portland, ME); David S. Frank (Springfield, NJ); John R Zeman (Springfield, NJ); Charles T. Tackney (Springfield, NJ)
Assignee: DNA Genotek, INC.
G01N33/5091G01N33/5005G01N33/54393G01N2333/16G01N2333/70514G01N2333/70517
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,038,434
App. No.
15/549,975
Granted
Jul 16, 2024
Kind
B2
Abstract

A solution is described for preserving cells and/or extra-cellular components in naturally expressed bodily fluids (e.g. saliva, sputum, urine) for further downstream analysis and/or for diagnosis of a medical condition. The solution may be hypertonic with respect to blood. Techniques are described for enriching cells from a sample of a naturally expressed bodily fluid, and/or for analysis, e.g. to diagnose medical conditions such as cancer, obesity, infections, autism, Alzheimer disease, hetotological disorders, cardiovascular disease or disorders, diabetes, vulnerable plack, LTBI, HIV infection, COPD, ACQS.

Claims (39)

1. A method of diagnosing and/or monitoring cancer in a subject, comprising:

obtaining a saliva sample from the subject;

stabilizing cells, proteins, free-floating DNA, and free-floating RNA in the saliva sample by contacting the saliva sample with a preservation solution to form a mixture, wherein the proteins, free-floating DNA, and free-floating RNA are extracellular components of the saliva sample,

wherein the preservation solution includes paraformaldehyde, at least one serum protein from human and/or other animal species, and sodium azide, and wherein the preservation solution is buffered at a pH from 6.4 to 8.4;

storing the mixture at room temperature;

subsequently separating the proteins, free-floating DNA, and free-floating RNA from the cells; and

analyzing two or more analytes selected from the proteins, free-floating DNA, and free-floating RNA to diagnose and/or monitor the cancer, wherein the step of analyzing comprises molecular analysis.

2. The method of claim 1 , wherein the cancer is lung cancer, lung carcinoma, leukemia, or non-small cell lung carcinoma.

3. The method of claim 1 , wherein the at least one serum protein from human and/or other animal species comprises fetal bovine serum.

4. The method of claim 3 , wherein the preservation solution comprises 1% (v/v) paraformaldehyde, 1% (v/v) fetal bovine serum, and 0.01% (w/v) sodium azide, and the preservation solution is buffered at a pH of 7.4.

5. The method of claim 1 , wherein the saliva sample and the preservation solution are contacted at a 1:1 ratio by volume.

6. The method of claim 1 , wherein the proteins, free-floating DNA, and/or free-floating RNA are separated from the cells by centrifugation.

7. The method of claim 1 , wherein the step of analyzing comprises sequencing.

8. The method of claim 7 , wherein the step of analyzing comprises whole genome sequencing.

9. The method of claim 7 , wherein the step of analyzing comprises RNA sequencing.

10. The method of claim 7 , wherein the step of analyzing comprises DNA sequencing.

11. The method of claim 7 , wherein the step of analyzing comprises epigenetic sequencing.

12. The method of claim 1 , further comprising determining a drug treatment for the subject.

13. The method of claim 1 , further comprising analyzing the cells.

14. The method of claim 1 , wherein the cancer is lung cancer.

15. The method of claim 1 , wherein the two or more analytes are selected from free-floating DNA and free-floating RNA.

16. A method of diagnosing and/or monitoring, and treating cancer in a subject, comprising:

obtaining a saliva sample from the subject;

stabilizing cells, proteins, free-floating DNA, and free-floating RNA in the saliva sample by contacting the saliva sample with a preservation solution to form a mixture, wherein the proteins, free-floating DNA, and free-floating RNA are extracellular components of the saliva sample,

wherein the preservation solution includes paraformaldehyde, at least one serum protein from human and/or other animal species, and sodium azide, and wherein the preservation solution is buffered at a pH from 6.4 to 8.4;

storing the mixture at room temperature;

subsequently separating the proteins, free-floating DNA, and free-floating RNA from the cells;

analyzing two or more analytes selected from the proteins, free-floating DNA, and free-floating RNA to diagnose and/or monitor the cancer, wherein the step of analyzing comprises molecular analysis;

determining a drug treatment for the subject; and

administering the drug treatment to the subject.

17. The method of claim 16 , wherein the two or more analytes are selected from free-floating DNA and free-floating RNA.

18. A method of diagnosing and/or monitoring cancer in a subject, comprising:

obtaining a saliva sample from the subject;

stabilizing cells, proteins, free-floating DNA, and free-floating RNA in the saliva sample by contacting the saliva sample with a preservation solution to form a mixture, wherein the proteins, free-floating DNA, and free-floating RNA are extracellular components of the saliva sample,

wherein the preservation solution includes paraformaldehyde, at least one serum protein from human and/or other animal species, and sodium azide, and wherein the preservation solution is buffered at a pH from 6.4 to 8.4;

storing the mixture at room temperature;

subsequently separating the proteins, free-floating DNA, and free-floating RNA from the cells; and

analyzing two or more analytes selected from the proteins, free-floating DNA, and free-floating RNA to diagnose and/or monitor the cancer;

wherein the cancer is lung cancer.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 4, 2020
From: ABOGEN, INC.
To: DNA GENOTEK, INC.
Reel/Frame 052845/0599 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 4, 2020
From: ANDREWS, STEPHEN; BIADILLAH, YOUSSEF; JAIN, MANASI; FRANK, DAVID S.; ZEMAN, JOHN R.; TACKNEY, CHARLES T.
To: ABOGEN, INC.
Reel/Frame 052016/0035 →
Priority Claims (6)
EP 15154381 · Feb 9, 2015 · regional
EP 15164155 · Apr 17, 2015 · regional
EP 15164567 · Apr 21, 2015 · regional
EP 15173040 · Jun 21, 2015 · regional
EP 15196908 · Nov 28, 2015 · regional
EP 16153712 · Feb 1, 2016 · regional
Continuity (1)
Related Publication 20180031543A1 · Feb 1, 2018